CL2014000992A1 - Preparacion de liberacion sostenida que comprende pioglitazona o una sal de esta; metodo de preparacion; uso para prevenir y/o retardar el inicio o suprimir la progresion de la enfermedad de alzheimer. - Google Patents

Preparacion de liberacion sostenida que comprende pioglitazona o una sal de esta; metodo de preparacion; uso para prevenir y/o retardar el inicio o suprimir la progresion de la enfermedad de alzheimer.

Info

Publication number
CL2014000992A1
CL2014000992A1 CL2014000992A CL2014000992A CL2014000992A1 CL 2014000992 A1 CL2014000992 A1 CL 2014000992A1 CL 2014000992 A CL2014000992 A CL 2014000992A CL 2014000992 A CL2014000992 A CL 2014000992A CL 2014000992 A1 CL2014000992 A1 CL 2014000992A1
Authority
CL
Chile
Prior art keywords
preparation
pioglitazone
alzheimer
onset
progression
Prior art date
Application number
CL2014000992A
Other languages
English (en)
Inventor
Yumiko Ishii
Yutaka Tanque
Yusuke Murakawa
Kaoru Takenaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000992(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CL2014000992A1 publication Critical patent/CL2014000992A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014000992A 2011-10-21 2014-04-17 Preparacion de liberacion sostenida que comprende pioglitazona o una sal de esta; metodo de preparacion; uso para prevenir y/o retardar el inicio o suprimir la progresion de la enfermedad de alzheimer. CL2014000992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21

Publications (1)

Publication Number Publication Date
CL2014000992A1 true CL2014000992A1 (es) 2014-09-05

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000992A CL2014000992A1 (es) 2011-10-21 2014-04-17 Preparacion de liberacion sostenida que comprende pioglitazona o una sal de esta; metodo de preparacion; uso para prevenir y/o retardar el inicio o suprimir la progresion de la enfermedad de alzheimer.

Country Status (29)

Country Link
US (1) US9907789B2 (es)
EP (1) EP2768487B1 (es)
JP (1) JP6093762B2 (es)
KR (1) KR20140081826A (es)
CN (1) CN104039313A (es)
AP (1) AP2014007645A0 (es)
AR (1) AR088398A1 (es)
AU (1) AU2012326976B2 (es)
BR (1) BR112014008744A2 (es)
CA (1) CA2852417A1 (es)
CL (1) CL2014000992A1 (es)
CO (1) CO6960544A2 (es)
CR (1) CR20140213A (es)
DO (1) DOP2014000077A (es)
EA (1) EA201490840A1 (es)
EC (1) ECSP14013328A (es)
IL (1) IL232114A0 (es)
IN (1) IN2014DN03169A (es)
MA (1) MA35717B1 (es)
MX (1) MX2014004679A (es)
NZ (1) NZ624275A (es)
PE (1) PE20141189A1 (es)
SG (2) SG2014012025A (es)
TN (1) TN2014000152A1 (es)
TW (1) TW201323018A (es)
UA (1) UA113858C2 (es)
UY (1) UY34403A (es)
WO (1) WO2013058409A1 (es)
ZA (1) ZA201403103B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104039313A (zh) 2011-10-21 2014-09-10 武田药品工业株式会社 缓释制剂
MD20140063A2 (ro) 2012-04-20 2014-12-31 Gilead Sciences, Inc. Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
SK281042B6 (sk) 1992-09-18 2000-11-07 Yamanouchi Pharmaceutical Co., Ltd Prípravok hydrogélového typu s ustáleným uvoľňovaním
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
WO2003013609A1 (en) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
WO2004026241A2 (en) 2002-09-20 2004-04-01 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
IN192749B (es) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
BRPI0410555A (pt) 2003-06-06 2006-06-20 Takeda Pharmaceutical preparação sólida
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
WO2005099760A1 (ja) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited 固形製剤
EP1789022A2 (en) 2004-08-31 2007-05-30 Pfizer Products Incorporated Controlled release dosage forms combining immediate release and sustained release of low-solubility drug
WO2007038115A2 (en) 2005-09-22 2007-04-05 Sb Pharmco Puerto Rico Inc. Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
BRPI0620020A2 (pt) 2005-12-22 2011-10-25 Takeda Pharmaceutical preparação sólida, e, partìcula revestida
CN101410103B (zh) 2006-03-30 2013-04-10 日本脏器制药株式会社 固体药物制剂
TW200800299A (en) 2006-04-27 2008-01-01 Takeda Pharmaceutical Pharmaceutical composition
US9095519B2 (en) 2007-02-09 2015-08-04 Alphapharm Pty Ltd Dosage form containing two or more active pharmaceutical ingredients in different physical forms
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
AU2009298684B2 (en) 2008-09-30 2015-11-19 Konstantinos Ritis Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
JP5827952B2 (ja) 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
CN101884627B (zh) 2010-07-07 2012-01-25 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
KR20180050420A (ko) * 2011-01-10 2018-05-14 진판델 파마슈티컬스 인코포레이티드 알츠하이머 병 치료를 위한 방법 및 약품
CN104039313A (zh) 2011-10-21 2014-09-10 武田药品工业株式会社 缓释制剂
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Also Published As

Publication number Publication date
EP2768487A1 (en) 2014-08-27
BR112014008744A2 (pt) 2017-04-18
AU2012326976A1 (en) 2014-05-29
US20140248362A1 (en) 2014-09-04
WO2013058409A1 (en) 2013-04-25
TW201323018A (zh) 2013-06-16
SG2014012025A (en) 2014-06-27
AU2012326976A2 (en) 2014-06-12
PE20141189A1 (es) 2014-09-24
CR20140213A (es) 2014-06-18
AR088398A1 (es) 2014-05-28
TN2014000152A1 (en) 2015-09-30
IN2014DN03169A (es) 2015-05-22
US9907789B2 (en) 2018-03-06
EA201490840A1 (ru) 2014-08-29
ZA201403103B (en) 2015-08-26
UA113858C2 (uk) 2017-03-27
AU2012326976B2 (en) 2017-08-17
AP2014007645A0 (en) 2014-05-31
IL232114A0 (en) 2014-06-30
JP2014530802A (ja) 2014-11-20
JP6093762B2 (ja) 2017-03-08
UY34403A (es) 2013-05-31
NZ624275A (en) 2016-09-30
EP2768487B1 (en) 2020-06-03
MA35717B1 (fr) 2014-12-01
KR20140081826A (ko) 2014-07-01
CO6960544A2 (es) 2014-05-30
MX2014004679A (es) 2014-08-01
SG10201700121YA (en) 2017-03-30
ECSP14013328A (es) 2014-05-31
CA2852417A1 (en) 2013-04-25
DOP2014000077A (es) 2014-07-15
CN104039313A (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
CR20130406A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
CL2014000370A1 (es) Hemifumarato de tenofovir alafenamida; metodo de preparación; composicion farmaceutica que lo comprende; metodo para preparar la composicion farmaceutica; y uso en el tratamiento de una infeccion por hiv.
EP2773637A4 (en) BENZOLSULFONAMIDE COMPOUNDS AND THEIR USE AS MEDICAMENTS
BR112013018953A2 (pt) composição efervescente na forma sólida para uso em aplicações vaginais para o tratamento de infecções vaginais.
CL2013002341A1 (es) Compuestos derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4 d]pirimidin-4-ona, inhibidores de pde9a; composicion farmaceutica; y su uso para el tratamiento de una enfermedad o afección relacionado con deterioro cognitivo, enfermedad de alzheimer, demencia vascular, entre otros
CO6801754A2 (es) Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
BR112014008089A2 (pt) método para diagnosticar o mal de alzheimer, uso do método, e, kit para a realização do método
BR112014029705A2 (pt) composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
CL2013003094A1 (es) Composiciones activas de antitranspirante que comprende una sal de aluminio y una especie de cation polihidroxioxoaluminio; metodo de fabricacion de la misma; y su uso.
CL2016001546A1 (es) Composición para el cuidado oral que comprende serina y al menos una sal de zinc.
CL2013003198A1 (es) Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.
CL2014000992A1 (es) Preparacion de liberacion sostenida que comprende pioglitazona o una sal de esta; metodo de preparacion; uso para prevenir y/o retardar el inicio o suprimir la progresion de la enfermedad de alzheimer.
EP2758384A4 (en) PHENYLIMIDE-CONTAINING BENZOTHIAZOL DERIVATIVES OR ITS SALT AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
CL2014000792A1 (es) Composicion para uso en la promocion de absorcion de magnesio y/o retencion de magnesio
CL2014000509A1 (es) Co-cristales que comprenden ciprodinil y ditianon; proceso para preparar los co-cristales; composicion para la proteccion de cultivos que comprende dichos co-cristales; uso para combatir hobgos fitopatógenos.
ES2445016B1 (es) Vacuna para el tratamiento/la prevencion de escuticociliatosis en peces
BR112014013227A2 (pt) uso de álcoois peguilados no tratamento de queratose actínica
BR112014013033A2 (pt) composição microbicida, composição de barra de sabão, método para fornecer um efeito microbicida para a pele e uso da composição
CL2014000489A1 (es) Forma de cristal anhidra de rilapladib, forma 3; composicion farmaceutica que lo comprende; combinacion farmaceutica; su uso en el tratamiento de la enfermedad de alzheimer.